Biomarkers in Tissue Samples From Patients With Ewing Sarcoma

Children's Oncology Group

Status: Completed

Conditions: Sarcoma

Treatments: Genetic: polymorphic microsatellite marker analysis; Genetic: polymerase chain reaction; Genetic: gene expression analysis; Genetic: DNA analysis; Genetic: mutation analysis; Genetic: comparative genomic hybridization; Other: laboratory biomarker analysis

Study type: Observational

Funder types: NETWORK; NIH

Identifiers

NCT01480518

COG-AEWS11B2 (Other Identifier)

AEWS11B2 (Other Identifier)

NCI-2012-00083 (Registry Identifier)

Details and patient eligibility

About

RATIONALE: Studying samples of tissue in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors understand how well patients respond to treatment.

PURPOSE: This research study is studying biomarkers in tissue samples from patients with Ewing sarcoma.

Full description

OBJECTIVES:

• To describe the spectrum of GGAA-microsatellite polymorphisms at specific loci in genomic DNA prepared from Ewing sarcoma tumor specimens.
• To determine if there are differences in GGAA-microsatellite polymorphisms in genomic DNA prepared from Ewing sarcoma tumor specimens as compared to non-afflicted European and African normal genomic DNA.
• To determine if GGAA-microsatellite polymorphisms at specific loci in genomic DNA prepared from Ewing's sarcoma tumor specimens correlates with disease outcome in patients treated on COG protocol AEWS0031.
• To determine whether whole-genome amplification introduces alterations in GGAA-microsatellites as compared to non-amplified genomic DNA.

OUTLINE: Genomic PCR is used to amplify the microsatellites in the NR0B1 and GSTM4 promoters. In addition to determining microsatellite size, each microsatellite is sequenced following cloning into the pCR4 vector (Invitrogen) using standard topoisomerase cloning protocols.

Enrollment: 166 patients

Sex: All

Ages: Under 50 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

• Specimens from patients with Ewing sarcoma used for protocol COG-AEWS08B1

  • Obtained from patient samples taken from patients enrolled on COG-AEWS0031
  • Whole genome-amplified DNA will be used

PATIENT CHARACTERISTICS:

• Not specified

PRIOR CONCURRENT THERAPY:

• Not specified